Biotech Discussion… continued

by Travis Johnson, Stock Gumshoe | February 5, 2018 10:36 am

This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.

Source URL: https://www.stockgumshoe.com/2018/02/biotech-discussion-continued/


1,710 responses to “Biotech Discussion… continued”

  1. SoGiAm says:

    Scientists develop artificial muscle that can repair damaged hearts.

    #scientists #muscle #heartfailure TY
    https://twitter.com/HashemGhaili/status/1063078461026287617 Best

  2. Griffin says:

    $FYI – Sticky hydrogel could revolutionize knee surgery

    “The researchers have already proven that the hydrogel can adhere to several types of tissues. Going forward, they plan to load it with different agents typically used for treatment and to tailor it to specific applications. ”

    Makes you wonder if there is any relationship to AC5.

    https://www.engadget.com/2018/11/23/sticky-hydrogel-epfl-cartilage/?yptr=yahoo

  3. Griffin says:

    $FYI – VitalTag to give vital information in mass casualty incidents

    “RICHLAND, Wash. — When mass casualty incidents occur — shootings, earthquakes, multiple car pile ups — first responders can easily be overwhelmed by the sheer number of victims. When every second counts, monitoring all the victims in a chaotic situation can be difficult. Researchers at the U.S. Department of Energy’s Pacific Northwest National Laboratory developed a stick-on sensor that measures and tracks a patient’s vital signs to help first responders quickly triage, treat and transport the injured.”

    https://www.pnnl.gov/news/release.aspx?id=4531&utm_campaign=News%20Releases&utm_source=hs_email&utm_medium=email&utm_content=67807880&_hsenc=p2ANqtz-8XPQAU6hrZT8K36cam2xZo1jAatOGLQzqNGYDspjU4ILj2KEgN_9gm8lyo9UsuateW_UOC5wD8gkIKggEfoj8YA-oD6A&_hsmi=67807880

  4. niizajim says:

    #CRMD no position, but interested.

    Their trial for their medical device was stopped by the FDA back in the summer for efficacy. They plan on a meeting with the FDA in Dec. to discuss the trial results and see if those results are enough to go ahead and file an NDA. Looks intriguing to me. They have cash through Q2 ’19 so will be raising at some point in the near future. Perhaps after stock receives some good news? Stock has recently risen 125% . Anyway, just eyeing this one right now.

  5. dunnydame says:

    $ZFGN long And if you’re wondering why the share price plummeted today.
    https://www.fool.com/investing/2018/11/26/why-zafgen-stock-is-crashing-today.aspx

    Why Zafgen Stock Is Crashing Today
    News of an FDA clinical hold zaps Zafgen’s share price.
    Keith Speights (TMFFishBiz) Nov 26, 2018 at 12:15PM
    What happened

    Zafgen (NASDAQ:ZFGN) stock crashed on Monday, with shares plunging 41.9% as of 11:12 a.m. EST. This huge drop came after the clinical-stage biotech announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on the Investigational New Drug Application (IND) for experimental type 2 diabetes drug ZGN-1061.

    The FDA’s decision to place a clinical hold on any clinical testing of ZGN-1061 stemmed from concerns about the potential for cardiovascular safety risk “based on the company’s prior compound.” This referenced Zafgen’s previous obesity drug, beloranib, which the company abandoned after patients died in late-stage studies. Both beloranib and ZGN-1061 are MetAP2 inhibitors. (And a little more . . . )

  6. eemajin says:

    “Rutgers University and BioViva USA, Inc. join forces to create a vaccine against aging”

    “The long-term goal is to establish a platform for clinical trial studies using a novel human cytomegalovirus (HCMV) as a vector and to develop a multi-gene therapeutic aging vaccine. BioiViva has already applied for the patent.”

    https://www.eurekalert.org/pub_releases/2018-12/bui-rua121018.php?utm_source=BioViva&utm_campaign=69367e9d21-EMAIL_CAMPAIGN_2019_01_03_11_43&utm_medium=email&utm_term=0_80fcf8e2fc-69367e9d21-284054517

    eemajin

  7. Koss says:

    $akao Entered at $1.38 share last week. Small position. Have been in and out of this one for awhile. Am concerned about cash position..obviously..however a company fire sale appears to be likely. As many may know they had a partial Phase 3 approval months back on their antibiotic they later unfortunately named Zemdri. Any thoughts on their near future potential or lack thereof?

  8. JoeS says:

    AUPH- Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

  9. finventurer says:

    Anybody remember us gummies talking about principals/basics of biotech investing and which thread was it?

    Now that there’s been some instability and volatility in markets i thought it would be good time to refresh memory and recap the basics but i cannot seem to locate the source.

    yours gratefully and apologizingly for the inconvenience, Finn

  10. Koss says:

    $auph np Hi Joe S..Any thoughts on today’s runup on auph? I didn’t see any news..some boards inficated a large block sold..maybe instututional?

  11. pvbemmelen says:

    Anyone a view on why CWBR is tanking so hard the last few days (beyond its general volatility).

  12. vmsk33094 says:

    Anyone an idea why price of CWBR increased so much to-day on high volume.

  13. vmsk33094 says:

    CWBR sp
    Anyone an idea why price of CWBR increased so much to-day on high volume.

  14. Griffin says:

    $ASX:IBX – 2019 World Molecular Imaging Conference Poster

    “The study shows MagSense nanoparticles may be equally effective as a multi-modal molecular imaging agint, generating detectable signals in two different imaging methods — superparamagnetic relaxometry (SPMR) and magnetic resonance imaging (MRI).”

    https://imagionbiosystems.com/2019-world-molecular-imaging-conference-poster/

    $ASX:IBX long

  15. Griffin says:

    $ASX:IBX – Scientific Advisory Board Established as IBX Advances towards First-in-Human Study

    https://imagionbiosystems.com/scientific-advisory-board-established/

    $IBX going longer

  16. Griffin says:

    $CMXC – This Bioelectric Breakthrough Could Disrupt The $300 Billion Diabetes Market

    “Cell MedX’s eBalance technology uses a spark to regenerate cells, much in the way nature does with animals, such as amphibians, which are able to regrow organs and limbs.[3]

    Like cracking the genetic code, the regeneration science behind Cell MedX’s technology is a true 21st century story. It’s another example of science fiction becoming reality.”

    https://thebullreport.com/this-bioelectric-breakthrough-could-disrupt-the-300-billion-diabetes-market/?utm_campaign=TI&utm_content=&utm_source=Yahoo&utm_medium=CPC&utm_term=

    CMXC np

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.